Genetic insights are reshaping how we understand the development and comorbidities of psoriasis, as well as treatment response in patients. Hear Dr. Audrey Bui discuss how genetic variants influence risks for certain conditions, how they may predict response to therapies like methotrexate, ustekinumab, and IL-17 inhibitors, and how integrating genetic markers into clinical care can enable more targeted, effective psoriasis management. Dr. Bui is a recent graduate from Lake Erie College of Osteopathic Medicine and an intern at the University of Central Florida prior to starting her dermatology residency at Hackensack Meridian Health Palisades Medical Center.

Inflammatory skin diseases like psoriasis don’t just affect the skin—they can often reflect broader cardiovascular risks. Given the overlap between dermatology and cardiology, knowing how to spot warning signs early and what steps to take during routine visits is key to comprehensive care. Joining Dr. Mary Cheeley to discuss the connection between the skin and the heart are Drs. Joel Gelfand and Michael Garshick. Dr. Gelfand is a dermatologist at the University of Pennsylvania and the Director of the Psoriasis and Phototherapy Treatment Center and the Center for Clinical Sciences in Dermatology. Dr. Garshick is a cardiologist and the Director of the Cardio-Rheumatology Program at NYU Langone Health, as well as an Assistant Professor of Medicine and Dermatology at NYU Grossman School of Medicine.

Home-based narrowband UVB phototherapy may offer a more accessible and effective option for managing psoriasis, as shown by the results of a recent study. With benefits like improved adherence, lower costs, and greater accessibility, this approach offers a compelling alternative for patients managing chronic disease. Explore the implications of this research and how it could shape future clinical practice with Dr. Joel Gelfand and Valerie Harrison. Dr. Gelfand is the Director of the Psoriasis and Phototherapy Treatment Center and the Center for Clinical Sciences in Dermatology at the University of Pennsylvania, as well as the lead investigator of the LITE study. Valerie Harrison is a study participant and a member of the National Psoriasis Foundation’s Board of Directors.

Psoriasis affects nearly eight million adults in the US, but its impact isn’t felt equally; significant disparities in diagnosis exist across race, ethnicity, and socioeconomic status. Join Dr. Joe Tung as he discusses his recent analysis of data from the National Health Interview Survey, in which he explored the most affected patient populations, the potential for underdiagnosis, and the broader ties between psoriasis, metabolic health, and life satisfaction. Dr. Tung is a board-certified dermatologist currently serving as the Medical Director of UPMC Falk Dermatology, Director of the Clinical Trials Unit, and Associate Director of the Dermatology Residency Program.

Psoriasis is more than just a skin condition—it can significantly impact a patient’s relationships, daily functioning, and overall quality of life. Tune in to hear Dr. Philip J. Mease discuss the multidimensional nature of psoriasis and the importance of a holistic approach to care. Dr. Mease is the Director of Rheumatology Research at Providence Swedish Medical Center and Clinical Professor at the University of Washington.

While systemic therapies like deucravacitinib have previously only been recommended for patients with moderate-to-severe plague psoriasis, it may be worth questioning whether body surface area alone is enough to dictate its use. Learn when scalp psoriasis may call for systemic therapies with Dr. Andrew Blauvelt, a dermatologist and clinical researcher with a focus on innovative treatments for psoriasis.

From novel oral therapies to advancements in biologic injections, the treatment landscape for psoriasis is rapidly evolving. Here to share his insights on how these new treatment strategies could improve efficacy, reduce safety concerns, and even make once-yearly biologic dosing a reality is Dr. Andrew Blauvelt. Dr. Blauvelt is a dermatologist and clinical researcher with a focus on innovative treatments for psoriasis.

Researchers speculate that the Mediterranean Diet may have benefits for psoriasis patients because of its anti-inflammatory effects. In fact, a recent study has been examining the relationship between the Mediterranean Diet and factors like skin health, quality of life, and markers of inflammation in the blood. Join Dr. Joel M. Gelfand, Director of the Psoriasis and Phototherapy Treatment Center and Director of the Center for Clinical Sciences in Dermatology at the University of Pennsylvania’s Perelman School of Medicine, as he discusses this study and its potential impacts on psoriasis care.

A recent retrospective study using the Alberta Health Services Data Repository of Reporting found that patients with psoriasis had a significantly lower lifespan than a control group of patients with a comparable health profile. Join Dr. Robert Gniadecki, Professor and Director of the Division of Dermatology at the University of Alberta, as he dives into this data and explains implications for clinical practice.

As the only FDA-designated selective TYK2 inhibitor, deucravacitinib has emerged as a potential therapeutic option for scalp psoriasis. And after analyzing its impacts in a phase III clinical trial, it has continued to show promise in terms of both efficacy and safety. Hear more about deucravacitinib and how it compares to alternate options like JAK inhibitors from Dr. Andrew Blauvelt, a dermatologist and clinical researcher with a focus on innovative treatments for psoriasis.